文献速递免疫规划传染病防控与疫情报告

RTS,S/AS01E疟疾疫苗在真实世界中三剂基础免疫后1年随访的有效性:加纳、肯尼亚和马拉维4期研究的期中分析

Effectiveness of the RTS,S/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi.
PubMed 文献 · Lancet Glob Health · 2025-11-06

EPI-MAL-003是一项4期疾病监测研究,在加纳、肯尼亚和马拉维12个站点比较接种RTS,S/AS01E的暴露组与未暴露组儿童。期中分析显示,接种组任何疟疾、重症疟疾、疟疾相关住院和全因住院的发病率均显著降低,全因死亡率无显著差异。

要点

  • 接种RTS,S/AS01E后1年随访,任何疟疾发病率比为0.70(95%CI 0.67-0.73)。
  • 重症疟疾发病率比为0.42(95%CI 0.30-0.60),疟疾相关住院为0.64(95%CI 0.56-0.72)。
  • 全因死亡率发病率比为0.83(95%CI 0.64-1.09),无显著差异。

核心结论

  • 真实世界中接种RTS,S/AS01E后1年随访显示疟疾负担显著降低,支持继续在儿童中使用该疫苗作为减少疟疾相关疾病和死亡的有效公共卫生措施。

研究设计与样本

  • EPI-MAL-003是一项4期疾病监测研究,采用前瞻性队列事件监测,在加纳、肯尼亚和马拉维12个站点(每国4个)的常规医疗实践环境中开展。
  • 研究纳入18个月以下儿童,分为暴露组(已引入RTS,S/AS01E的站点)和未暴露组,通过主动监测收集数据。
  • 期中分析评估三剂RTS,S/AS01E基础免疫后1年随访内对疟疾发病率、全因住院、疟疾相关住院、住院儿童贫血患病率和死亡率的影响,分析集包含39463名儿童。

主要发现

  • 暴露组接种儿童与未暴露组未接种儿童相比,经国家调整的任何疟疾发病率比为0.70(95%CI 0.67-0.73;p<0.001)。
  • 重症疟疾发病率比为0.42(95%CI 0.30-0.60;p<0.001),疟疾相关住院发病率比为0.64(95%CI 0.56-0.72;p<0.001)。
  • 全因住院发病率比为0.79(95%CI 0.74-0.84;p<0.001),全因死亡率发病率比为0.83(95%CI 0.64-1.09;p=0.18)。
  • 住院儿童贫血患病率的调整比值比为0.81(95%CI 0.73-0.90;p<0.001)。
  • 与RTS,S/AS01E引入前EPI-MAL-002研究中未接种儿童的前后比较也观察到类似趋势。

临床怎么用

  • 作者认为,这些发现强化了继续在儿童中使用RTS,S/AS01E疫苗接种作为减少疟疾相关疾病和死亡的有效公共卫生措施,并凸显其对未来疟疾控制策略的相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RTS,S/AS01E was first introduced within the Malaria Vaccine Implementation Programme in selected areas in Ghana, Kenya, and Malawi. A series of post-introduction observational studies were initiated in these areas to assess RTS,S/AS01E safety and effectiveness in real-world settings. Here, we report the results of the interim analysis of the EPI-MAL-003 study secondary objectives related to vaccine effectiveness. METHODS: EPI-MAL-003 was a phase 4, disease surveillance study with prospective cohort event monitoring. The study was performed in routine medical practice settings at 12 sites (four per country) in Ghana, Kenya, and Malawi. Children younger than 18 months were enrolled in exposed clusters (sites where RTS,S/AS01E was introduced) and unexposed clusters; data were collected via active surveillance. In an interim analysis, we estimated the effect of vaccination on the incidence of malaria, all-cause hospitalisations, and malaria-related hospitalisations, the prevalence of anaemia among hospitalised children, and mortality over 1 year of follow-up after primary vaccination with three RTS,S/AS01E doses. These endpoints were analysed in the effectiveness analysis set. The primary endpoints are reported elsewhere, together with secondary safety endpoints. This study is registered with ClinicalTrials.gov, NCT03855995, and is completed. FINDINGS: The first child was enrolled on March 21, 2019, and the cutoff date for the current analysis was Nov 2, 2023. 45 000 children were enrolled (22 426 [49·8%] were female and 22 574 [50·25%] were male). 39 463 children were included in the analyses. When comparing vaccinated children from exposed clusters with unvaccinated children from unexposed clusters, country-adjusted incidence rate ratios were 0·70 (95% CI 0·67-0·73; p<0·001) for any malaria, 0·42 (0·30-0·60; p<0·001) for severe malaria, 0·64 (0·56-0·72; p<0·001) for malaria-related hospitalisations, 0·79 (0·74-0·84; p<0·001) for all-cause hospitalisations, and 0·83 (0·64-1·09; p=0·18) for all-cause mortality. The adjusted odds ratio for the prevalence of anaemia among children who were hospitalised (vaccinated children from exposed clusters vs unvaccinated children from unexposed clusters) was 0·81 (95% CI 0·73-0·90; p<0·001). Similar trends were observed in a before-after comparison with unvaccinated children enrolled in the EPI-MAL-002 study conducted before the RTS,S/AS01E introduction. INTERPRETATION: Over 1 year of follow-up after the third vaccine dose, vaccination with RTS,S/AS01E in real-world settings showed significant reductions in malaria burden. These findings reinforce the continued use of RTS,S/AS01E vaccination in children as an effective public health measure to reduce malaria-related illness and mortality in endemic regions, and highlight its relevance for future malaria control strategies. FUNDING: GSK.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Ndeketa L, Haine V, Debois M, et al. Effectiveness of the RTS,S/AS01E malaria vaccine in a real-world setting over 1 year of follow-up after the three-dose primary schedule: an interim analysis of a phase 4 study in Ghana, Kenya, and Malawi. Lancet Glob Health. 2025. PMID: 41207319. doi:10.1016/S2214-109X(25)00415-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。